DNM1L and Parkinson disease: In contrast, P110, a peptide inhibitor with reduced Drp1 enzyme activity, can prevent Drp1/Fis1 interaction between neurons, which can effectively improve mitochondrial morphology and reduce mitochondrial fission, thus reducing neuronal axon loss in Parkinson’s disease patients and thus acting as a neuroprotective agent (Qi et al., 2013).